fbpx

REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search

In a Collaboration Initiated by a Sheba Physician, Medical Researchers from More Than 130 Countries Are Working Together to Study Retinoblastoma

Study Retinoblastoma
Retinoblastoma is the most common pediatric intraocular malignancy and is fatal if left untreated. Global retinoblastoma research has been initiated by our physician in an endeavor to collect as much data as possible and improve the odds of treatment success.

While retinoblastoma is the most common pediatric intraocular malignancy, it is still a relatively rare malignancy. According to the latest estimations, only 8,000 new cases of retinoblastoma are diagnosed every year. Consequently, data concerning malignancy is scarce.

Retinoblastoma can be fatal if left untreated, so early diagnosis can save both a child’s life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. Realizing that the clinical presentation of retinoblastoma has never been assessed on a global scale, Dr. Ido Fabian from the Goldschleger Eye Institute at Sheba Medical Center initiated a border-crossing collaboration between 278 retinoblastoma treatment centers for the purpose of advancing a cross-sectional analysis of treatment-naive patients with retinoblastoma.

Today, the aptly named Global Retinoblastoma Study Group is one of the most extensive global cooperation programs in medicine, and incorporates most of the dedicated retinoblastoma treatment centers from around the world, including centers from Iran, Saudi Arabia, Libya, Yemen, Lebanon, Pakistan, Afghanistan and other countries that traditionally avoid contact with Israel and Israeli institutions.

In an unprecedented achievement, the Global Retinoblastoma Study Group managed to gather data on 4,351 new patients diagnosed in 2017, estimated to be more than half of all new retinoblastoma cases worldwide in 2017.

According to a study recently published by the group, current data from European countries demonstrate a higher estimate of the incidence of retinoblastoma than what has been reported for previous periods. The study concluded that the incidence of retinoblastoma has likely increased because of improved survival rates of patients attributable to more effective treatments, which appears to be the first time a selection relaxation effect of therapeutic intervention for a lethal disorder is evident after only a few generations.

Besides advancing research, the cooperation between retinoblastoma treatment centers from around the world contributed to other international collaborations, including the establishment of the Retinoblastoma Network (Rb-NET), founded by Dr. Fabian along with Dr. Rachel Shemesh and Dr. Ofri Berar Vorobichik from Sheba Medical Center. Rb-NET works to improve survival, salvage the eye, preserve vision and improve the quality of life of children diagnosed with retinoblastoma in remote and rural areas and developing nations. This is achieved by improving cooperation between health centers around the world and enabling effective dissemination of knowledge on retinoblastoma through an educational platform.

Related
Sheba Ranked Among the Top 10 Hospitals in the World by Newsweek
We are pleased to announce that for the sixth consecutive year, Sheba has been recognized as one of the best hospitals in the world by…
Read More
Doctor analyzing hemophilia blood with a microscope. The focus of the shot is on the blood.
Breakthrough Hemophilia Treatment by Prof. Gili Kenet Empowers Boy's Dream
Prof. Gili Kenet, a renowned pediatric hematologist at Sheba’s National Hemophilia Center and an esteemed professor at the Sackler School of Medicine, unveiled a groundbreaking…
Read More
Text "SCIENCE DOSE" with a magnifying glass next to it zooming in on cells and viruses. Additional elements include a syringe, microscope, and blood cells.
Navigating Retinoblastoma: Expert Analysis by Prof. Didi Fabian
Prof. Didi Fabian, a senior ocular oncologist at Sheba’s Goldschleger Eye Institute and Director of Sheba Global Ophthalmology, recently delved into retinoblastoma, an eye cancer…
Read More